Compare QSI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSI | CBIO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 252.6M |
| IPO Year | N/A | N/A |
| Metric | QSI | CBIO |
|---|---|---|
| Price | $1.39 | $15.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.88 | ★ $25.60 |
| AVG Volume (30 Days) | ★ 6.2M | 61.7K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,177,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $219.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $9.81 |
| 52 Week High | $5.77 | $21.40 |
| Indicator | QSI | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 72.03 |
| Support Level | $1.19 | $12.76 |
| Resistance Level | $1.40 | $15.40 |
| Average True Range (ATR) | 0.12 | 0.60 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 40.00 | 78.64 |
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.